APP processing and metabolism in corneal fibroblasts and epithelium as a potential biomarker for Alzheimer's disease.
Alzheimer Disease
/ complications
Amyloid beta-Protein Precursor
/ biosynthesis
Animals
Biomarkers
/ metabolism
Blotting, Western
Cells, Cultured
Corneal Dystrophies, Hereditary
/ genetics
Enzyme-Linked Immunosorbent Assay
Epithelium, Corneal
/ metabolism
Fibroblasts
/ metabolism
Gene Expression Regulation
Humans
Immunohistochemistry
Mice
RNA
/ genetics
Alzheimer's disease
Amyloid precursor protein
Biomarker
Cornea
Granular corneal dystrophy type 2
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
19
10
2018
revised:
18
02
2019
accepted:
17
03
2019
pubmed:
2
4
2019
medline:
18
2
2020
entrez:
2
4
2019
Statut:
ppublish
Résumé
Alzheimer's disease (AD) primarily affects the brain and is the most common form of dementia worldwide. Despite more than a century of research, there are still no early biomarkers for AD. It has been reported that AD affects the eye, which is more accessible for imaging than the brain; however, links with the cornea have not been evaluated. To investigate whether the cornea could be used to identify possible diagnostic indicators of AD, we analyzed the proteolytic processing and isoforms of amyloid precursor protein (APP) and evaluated the expression of AD-related genes and proteins in corneal fibroblasts from wild-type (WT) corneas and corneas from patients with granular corneal dystrophy type 2 (GCD2), which is related to amyloid formation in the cornea. Reverse transcription polymerase chain reaction (RT-PCR) analysis was used to assess the expression of AD-related genes, i.e., APP, ADAM10, BACE1, BACE2, PSEN1, NCSTN, IDE, and NEP. RT-PCR and DNA sequencing analysis demonstrated that isoforms of APP770 and APP751, but not APP695, were expressed in corneal fibroblasts. Moreover, the mRNA ratio of APP770/APP751 isoforms was approximately 4:1. Western blot analysis also demonstrated the expression of a disintegrin and metalloprotease domain-containing protein 10 (ADAM10), beta-site APP-cleaving enzyme 1 (BACE1), nicastrin, insulin degradation enzyme, and neprilysin in corneal fibroblasts. Among these targets, the levels of immature ADAM10 and BACE1 protein were significantly increased in GCD2 cells. The expression levels of APP, ADAM10, BACE1, and transforming growth factor-beta-induced protein (TGFBIp) were also detected by western blot in human corneal epithelium. We also investigated the effects of inhibition of the autophagy-lysosomal and ubiquitin-proteasomal proteolytic systems (UPS) on APP processing and metabolism. These pathway inhibitors accumulated APP, α-carboxy-terminal fragments (CTFs), β-CTFs, and the C-terminal APP intracellular domain (AICD) in corneal fibroblasts. Analysis of microRNAs (miRNAs) revealed that miR-9 and miR-181a negatively coregulated BACE1 and TGFBIp, which was directly associated with the pathogenesis of AD and GCD2, respectively. Immunohistochemical analysis indicated that APP and BACE1 were distributed in corneal stroma cells, epithelial cells, and the retinal layer in mice. Collectively, we propose that the cornea, which is the transparent outermost layer of the eye and thus offers easy accessibility, could be used as a potential biomarker for AD diagnosis and progression.
Identifiants
pubmed: 30930125
pii: S0014-4835(18)30774-7
doi: 10.1016/j.exer.2019.03.012
pii:
doi:
Substances chimiques
APP protein, human
0
Amyloid beta-Protein Precursor
0
Biomarkers
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-174Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.